TargetMol

W-372 F-18

Product Code:
 
TAR-T35102
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T35102-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
W-372 F-18 is a biochemical.
CAS:
1206722-92-0
Formula:
C14H9FN4OS
Molecular Weight:
299.31
Purity:
0.98
SMILES:
COc1ccc2c(n1)sc1nc(cn21)-c1ccc([18F])nc1

References

Lee JW, Lee HS, Na JO, Lee SM. Effect of adipose tissue volume on prognosis in patients with non-small cell lung cancer. Clin Imaging. 2018 May 4;50:308-313. doi: 10.1016/j.clinimag.2018.05.006. [Epub ahead of print] PubMed PMID: 29751203. Sah BR, Leissing CA, Delso G, Ter Voert EE, Krieg S, Leibl S, Schneider PM, Reiner CS, H?llner MW, Veit-Haibach P. Evaluation of multifunctional imaging parameters in gastro-oesophageal cancer using F-18-FDG-PET/CT with integrated perfusion CT. Q J Nucl Med Mol Imaging. 2018 May 10. doi: 10.23736/S1824-4785.18.03067-4. [Epub ahead of print] PubMed PMID: 29745630. Beinat C, Haywood T, Chen YS, Patel CB, Alam IS, Murty S, Gambhir SS. The Utility of [(18)F]DASA-23 for Molecular Imaging of Prostate Cancer with Positron Emission Tomography. Mol Imaging Biol. 2018 May 7. doi: 10.1007/s11307-018-1194-y. [Epub ahead of print] PubMed PMID: 29736561. Rogasch JMM, Hundsdoerfer P, Hofheinz F, Wedel F, Schatka I, Amthauer H, Furth C. Pretherapeutic FDG-PET total metabolic tumor volume predicts response to induction therapy in pediatric Hodgkin's lymphoma. BMC Cancer. 2018 May 3;18(1):521. doi: 10.1186/s12885-018-4432-4. PubMed PMID: 29724189; PubMed Central PMCID: PMC5934894.